|
Name |
(3S,12aS)-2,3,6,7,12,12a-hexahydro-3-(2-methylpropyl)pyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione
|
Molecular Formula | C18H21N3O2 | |
IUPAC Name* |
5-(2-methylpropyl)-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione
|
|
SMILES |
CC(C)CC1NC(=O)C2Cc3c([nH]c4ccccc34)CN2C1=O
|
|
InChI |
InChI=1S/C18H21N3O2/c1-10(2)7-14-18(23)21-9-15-12(8-16(21)17(22)20-14)11-5-3-4-6-13(11)19-15/h3-6,10,14,16,19H,7-9H2,1-2H3,(H,20,22)/t14-,16-/m0/s1
|
|
InChIKey |
UZHRHFQWNFOVHR-HOCLYGCPSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 311.39 | ALogp: | 2.0 |
HBD: | 2 | HBA: | 2 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 65.2 | Aromatic Rings: | 4 |
Heavy Atoms: | 23 | QED Weighted: | 0.895 |
Caco-2 Permeability: | -4.772 | MDCK Permeability: | 0.00002670 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.126 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.003 |
30% Bioavailability (F30%): | 0.176 |
Blood-Brain-Barrier Penetration (BBB): | 0.843 | Plasma Protein Binding (PPB): | 74.35% |
Volume Distribution (VD): | 0.79 | Fu: | 13.75% |
CYP1A2-inhibitor: | 0.263 | CYP1A2-substrate: | 0.26 |
CYP2C19-inhibitor: | 0.881 | CYP2C19-substrate: | 0.326 |
CYP2C9-inhibitor: | 0.616 | CYP2C9-substrate: | 0.956 |
CYP2D6-inhibitor: | 0.03 | CYP2D6-substrate: | 0.475 |
CYP3A4-inhibitor: | 0.845 | CYP3A4-substrate: | 0.505 |
Clearance (CL): | 4.614 | Half-life (T1/2): | 0.592 |
hERG Blockers: | 0.029 | Human Hepatotoxicity (H-HT): | 0.804 |
Drug-inuced Liver Injury (DILI): | 0.582 | AMES Toxicity: | 0.023 |
Rat Oral Acute Toxicity: | 0.829 | Maximum Recommended Daily Dose: | 0.502 |
Skin Sensitization: | 0.146 | Carcinogencity: | 0.05 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.012 |
Respiratory Toxicity: | 0.654 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005998 | 0.789 | D05MQK | 0.367 | ||||
ENC005997 | 0.640 | D01JGV | 0.308 | ||||
ENC005470 | 0.518 | D0U7GP | 0.308 | ||||
ENC000981 | 0.484 | D0U7GK | 0.297 | ||||
ENC004933 | 0.484 | D05EPM | 0.289 | ||||
ENC001926 | 0.479 | D06YFA | 0.287 | ||||
ENC004610 | 0.465 | D0H4JM | 0.284 | ||||
ENC000975 | 0.465 | D06BYV | 0.284 | ||||
ENC003217 | 0.448 | D0Q5NX | 0.283 | ||||
ENC005974 | 0.432 | D08VRO | 0.276 |